Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study

This study evaluated the safety, antitumor activity, pharmacokinetics, and pharmacodynamics of inotuzumab ozogamicin (InO) for CD22-positive relapsed/refractory acute lymphoblastic leukemia. In phase 1, patients received InO 1.2 (n = 3), 1.6 (n = 12), or 1.8 (n = 9) mg/m(2) per cycle on days 1, 8, a...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Blood Adv
Main Authors: DeAngelo, Daniel J., Stock, Wendy, Stein, Anthony S., Shustov, Andrei, Liedtke, Michaela, Schiffer, Charles A., Vandendries, Erik, Liau, Katherine, Ananthakrishnan, Revathi, Boni, Joseph, Laird, A. Douglas, Fostvedt, Luke, Kantarjian, Hagop M., Advani, Anjali S.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2017
Teme:
Clinical Trials and Observations
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5728308/
https://ncbi.nlm.nih.gov/pubmed/29296758
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2016001925
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki